Skip to main content
Claritas Pharmaceuticals, Inc. logo

Claritas Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CLAZF ISIN · CA1806342061 LEI · 529900L41UFXOXZ1G169 TSXV Manufacturing
Filings indexed 98 across all filing types
Latest filing 2022-07-22 Regulatory Filings
Country CA Canada
Listing TSXV CLAZF

About Claritas Pharmaceuticals, Inc.

https://claritaspharma.com/

Claritas Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products addressing areas of unmet medical need. The company maintains a portfolio of pharmaceutical candidates, with a primary focus on advancing its lead compound, R-107. R-107 is being developed as a potential therapy for various viral infections, including influenza and COVID-19. The company's development pipeline also explores treatments within therapeutic areas such as Nervous System Diseases.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2022-07-22 English
News release - English.pdf
Regulatory Filings
2022-07-22 English
News release - English.pdf
Regulatory Filings
2022-06-24 English
Material change report - English.pdf
Regulatory Filings
2022-05-16 English
News release - English.pdf
Regulatory Filings
2022-05-13 English
News release - English.pdf
Regulatory Filings
2022-05-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.